SEER-Medicare: Requirements of Investigators Following Receipt of the Data
Investigators who have received the SEER-Medicare data must abide by the policies established by NCI and the SEER program. These include the following:
- Researchers must send a copy of any manuscript or book chapter to the SEER-Medicare contact prior to submitting it to a journal for review. Please indicate the principal investigator and the approved project title when sending the manuscript. This review is to ensure the confidentiality of patients and providers in SEER areas and that the manuscript topic matches the approved project. The review is not intended for the purpose of assessing the scientific merit of a manuscript. Researchers are not required to submit copies of meeting abstracts, power point presentations or dissertations for review. However, all presentations and abstracts using SEER-Medicare data must comply with requirements about cell sizes, mapping and protection of patients and providers as described on the SEER-Medicare DUA (PDF, 170 KB). The SEER-Medicare linked data cell size suppression policy detailed in the SEER-Medicare DUA is the same as the CMS cell size policy.
- NCI would appreciate the inclusion of the following acknowledgment in any publication or presentations using SEER-Medicare
"This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database."
- Projects that use data from the California Cancer Registry or the Greater
Bay Area Cancer Registry are REQUIRED to include the following
"The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement # U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database."
- If investigators want to use the data they have received for another project, they must submit a new application and appropriate paperwork for review according to the instructions.
- Investigators moving / changing institutions must contact NCI prior to the move for instructions on how to handle SEER-Medicare data.
- Investigators may not provide SEER-Medicare data to any other individual or investigator. Contact NCI to discuss arrangements for ordering an extra copy of the dataset.
- Investigators may not link variables from the SEER-Medicare files to files other than SEER-Medicare without the written consent from the applicable SEER registries.
- Investigators may not publish or present findings in which the number of cases in a cell is less than eleven. This policy is to eliminate the potential for re-identification of persons with cancer.